Development of an optimal lidocaine infusion strategy for neonatal seizures.

Mirte M Malingré, Linda G M Van Rooij, Carin M A Rademaker, Mona C Toet, Tessa F F T Ververs, Charlotte van Kesteren, Linda S de Vries
Author Information
  1. Mirte M Malingré: Department of Pharmacy, University Medical Centre Utrecht/Wilhelmina Children's Hospital, Utrecht, The Netherlands.

Abstract

INTRODUCTION: Lidocaine is an effective drug for the treatment of neonatal convulsions not responding to traditional anticonvulsant therapy. However, one of the side-effects is a risk of cardiac arrhythmias. The aim of this study was to develop an optimal dosing strategy with minimal risk of cardiac arrhythmias.
MATERIALS AND METHODS: As a first step, we studied 20 neonates during routine treatment of neonatal seizures with lidocaine. All were given a loading dose of 2 mg/kg in 10 min, followed by the continuous infusion of 6 mg/kg per hour for 12 h, 4 mg/kg per hour for 12 h and finally 2 mg/kg per hour for 12 h. Effectiveness, cardiac toxicity and lidocaine plasma concentrations were then determined.
RESULTS: No cardiac arrhythmias were observed, and lidocaine was effective in 76% of the treatments. In most of the treatments (13 out of 20) maximal lidocaine plasma concentrations were >9 mg/L. Plasma levels >9 mg/L have been related to cardiac toxicity when used as an anti-arrhythmic drug in adults. It was of interest that all preterm infants showed high lidocaine plasma levels. Secondly, we developed the optimal dosing regimen, which was defined as an infusion regimen at which maximal lidocaine plasma concentrations are <9 mg/L. Simulations with the developed pharmacokinetic model indicated a reduction in the infusion duration of lidocaine at 6 mg/kg per hour from 12 to 6 h. Thirdly, the new lidocaine dosing regimen was evaluated. Fifteen neonates (16 treatments) were studied. No cardiac arrhythmias were observed, and lidocaine was effective in 78% of the treatments. In most of the treatments (11 out of 16) maximal lidocaine plasma concentrations were <9 mg/L. Again preterm infants showed relatively high lidocaine plasma levels.
CONCLUSION: A new lidocaine dosing schedule was developed. This new regimen should have a lower risk of cardiac arrhythmias and appears to be as effective in term infants. For preterm infants the optimal regimen needs to be determined.

References

  1. Eur J Pediatr. 2004 Nov;163(11):637-41 [PMID: 15309624]
  2. J Pediatr. 1982 Sep;101(3):461-3 [PMID: 7108671]
  3. Am Heart J. 1974 Dec;88(6):765-9 [PMID: 4417417]
  4. Clin Pharmacokinet. 1978 May-Jun;3(3):177-201 [PMID: 350470]
  5. Clin Pharmacol Ther. 2004 Jan;75(1):80-8 [PMID: 14749694]
  6. Br J Clin Pharmacol. 1998 Oct;46(4):307-19 [PMID: 9803978]
  7. Ther Drug Monit. 2000 Jun;22(3):320-2 [PMID: 10850400]
  8. N Engl J Med. 1974 Dec 19;291(25):1324-6 [PMID: 4610392]
  9. Ann Pharmacother. 1998 Jul-Aug;32(7-8):818-28 [PMID: 9681098]
  10. Pharm Res. 1995 Dec;12(12):1845-55 [PMID: 8786955]
  11. J Child Neurol. 2002 May;17(5):400-1 [PMID: 12150593]
  12. Acta Paediatr Scand. 1988 Jan;77(1):79-84 [PMID: 3369308]
  13. Chest. 1982 May;81(5):644-5 [PMID: 7075289]
  14. Ther Drug Monit. 1990 Jul;12(4):316-20 [PMID: 2396303]
  15. J Perinatol. 1998 May-Jun;18(3):193-5 [PMID: 9659647]
  16. Comput Methods Programs Biomed. 1999 Jan;58(1):51-64 [PMID: 10195646]
  17. J Pharmacol Exp Ther. 1973 Jul;186(1):31-6 [PMID: 4723312]
  18. N Engl J Med. 1967 Dec 7;277(23):1215-9 [PMID: 4862377]
  19. Acta Paediatr. 1992 Jan;81(1):35-9 [PMID: 1600301]

MeSH Term

Anti-Arrhythmia Agents
Anticonvulsants
Arrhythmias, Cardiac
Dose-Response Relationship, Drug
Follow-Up Studies
Gestational Age
Humans
Infant
Infant, Newborn
Infusions, Intravenous
Intensive Care Units, Neonatal
Lidocaine
Netherlands
Recurrence
Risk Factors
Seizures
Time Factors
Treatment Outcome

Chemicals

Anti-Arrhythmia Agents
Anticonvulsants
Lidocaine

Word Cloud

Created with Highcharts 10.0.0lidocainecardiacplasmaarrhythmiasmg/kgtreatmentsregimeneffectiveoptimaldosinginfusionperhour12hconcentrationsmg/Linfantsneonatalrisk6maximallevelspretermdevelopednewdrugtreatmentstrategystudied20neonatesseizures2toxicitydeterminedobserved>9showedhigh<916INTRODUCTION:LidocaineconvulsionsrespondingtraditionalanticonvulsanttherapyHoweveroneside-effectsaimstudydevelopminimalMATERIALSANDMETHODS:firststeproutinegivenloadingdose10minfollowedcontinuous4finallyEffectivenessRESULTS:76%13Plasmarelatedusedanti-arrhythmicadultsinterestSecondlydefinedSimulationspharmacokineticmodelindicatedreductiondurationThirdlyevaluatedFifteen78%11relativelyCONCLUSION:schedulelowerappearstermneedsDevelopment

Similar Articles

Cited By